Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
News|Articles|November 4, 2026

Quotient Sciences first-in-human to proof-of-concept studies

Early-phase drug development often stalls when development, manufacturing, and clinical activities operate independently. Learn how an integrated FIH-to-POC model can help address common bottlenecks, improve program continuity, and generate the data needed to make confident development decisions.


Related to this article